|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||191.13 - 192.50|
|52 Week Range||164.80 - 202.04|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
Some investors are eagerly betting on mid-cap ETFs.
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Skechers, which released its 2Q17 results on July 20, 2017, reported earnings per share of $0.38. The company missed analysts' consensus expectation by a margin of $0.06.